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Editorial p. 6
With the publication of the PARAGON-HF 
(The Prospective Comparison of ARNI [angio-
tensin receptor–neprilysin inhibitor] with ARB 
[angiotensin-receptor blockers] Global Outcomes 
in Heart Failure with Preserved Ejection Fraction) 
trial during the European Society of Cardiology 
Congress 2019 [1], cardiologists again faced the 
reality that there remains no convincing evidence-
proven strategy that can bring definitive benefit for 
heart failure (HF) with preserved ejection fraction 
(HFpEF). After hearing the news, many of the 
attendees’ mood turned as blue as the sky over 
Paris. Certainly, we should keep moving forward, 
but before that, why not wait a minute and think 
about where the problem of HFpEF is. 
To date, therapies tested in clinical trials on 
HFpEF have all been adopted from successful 
therapy concepts of heart failure with reduced 
ejection fraction (HFrEF). However, it seems to 
have been ignored that HF is a heterogeneous 
disease or syndrome, especially for HFpEF [2]. 
The heterogeneity in etiology and pathophysiol-
ogy, alone or in combination, of HFpEF patients 
might explain why successful approaches in HFrEF 
patients failed however in HFpEF. One way to 
solve the HFpEF problem might be to go back 
to  an etiology-oriented therapy principle and get 
rid of “one-size-fits-all” thinking mode. As early 
as 2012, it was pointed out that HFpEF patients 
should be phenotyped according to etiology in order 
to make targeted therapies in HFpEF subgroups 
[2]. Shah et al. [3] once introduced a clinical phe-
notypic classification of HFpEF, which included: 
(1) “garden-variety” HFpEF; (2) coronary artery 
disease-HFpEF; (3) right heart failure-predominant 
HFpEF; (4) atrial fibrillation-predominant HFpEF; 
(5) hypertrophic cardiomyopathy-like HFpEF; 
(6) valvular HFpEF; (7) high output HFpEF; and 
(8) rare cause of HFpEF. Although this classifica-
tion is oriented by the etiology and risk factors of 
HFpEF, its intrinsic complexity has prevented its 
widespread clinical use. Hence, here I proposed 
a new coding method on phenotyping HFpEF, 
following principles of simplicity, practicality, and 
comprehensiveness.
The view expressed herein is that HFpEF can 
be classified into five subtypes (Table 1): 
1. Vascular-related HFpEF. It includes HFpEF 
related to hypertension, coronary artery 
disease (CAD), and coronary microvascular 
dysfunction. Systemic and cardiac vascular 
abnormalities are both common in HFpEF, and 
that hypertension and CAD are considered the 
most prevalent cardiovascular comorbidities in 
HFpEF [4]. Furthermore, coronary microvas-
cular dysfunction is also a common pathophysi-
ological mechanism of HFpEF [4]. In these 
patients, hypertension or ischemia resulting 
from epicardial CAD or microvascular dysfunc-
tion plays a crucial role in the pathophysiology 
of HFpEF, so these patients might benefit from 
the HFrEF therapy strategy. 
2. Cardiomyopathy-related HFpEF. These pa-
tients may have hypertrophic cardiomyopa-
thy, infiltrative cardiomyopathies like cardiac 
amyloidosis and Fabry cardiomyopathy, etc. 
Diastolic dysfunction and elevation of left 
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ventricular filling pressure should be the un-
derlying pathophysiology in these patients. 
Specific therapies, like targeted surgery or 
intervention in obstructive hypertrophic car-
diomyopathy, tafamidis for transthyretin amy-
loidosis, enzyme replacement for Fabry should 
be considered in these cases. 
3. Right heart- and pulmonary-related HFpEF. 
Patients in this subtype often have pulmonary 
hypertension with or without right ventricular 
dysfunction. Actually, pulmonary hypertension 
and right ventricular dysfunction could result 
from increased left ventricular filling pres-
sure and left atrial hypertension, resulting in 
HFpEF in turn [3, 4]. Combined therapy from 
cardiologists and pulmonary specialists might 
be the key option for these patients.
4. Valvular- and rhythm-related HFpEF. Val-
vular diseases could lead to hemodynamic 
disorder in left and/or right heart, influencing 
the filling pressure and diastolic function fur-
ther. Rhythm-related HFpEF mainly refers to 
HFpEF in which atrial fibrillation is predomi-
nant. Patients in this category might benefit 
from surgical or interventional valve therapy 
and rhythm control therapy.
5. Extracardiac disease-related HFpEF. The extra-
cardiac diseases involve: (1) metabolic diseases, 
such as diabetes mellitus, obesity, or metabolic 
syndrome; (2) diseases that often cause a high 
output state, such as anemia, liver disease, 
hyperthyroidism, and arteriovenous fistula; 
(3) other diseases, such as chronic kidney dis-
ease, radiotherapy for cancer, etc. [5]. Again, 
etiology-oriented therapy options are needed 
for these patients, for instance, sodium-depend-
ent glucose transporters 2 (SGLT2) inhibitor, 
weight-reduction efforts and exercise might be 
effective for metabolic HFpEF. 
The new phenotype proposal for HFpEF is 
more structured than previously suggested [3]. 
The phenotypic coding not only helps introduce 
a better understanding about the risk factors, 
etiology, pathophysiology and clinical course of 
HFpEF, but also contributes to guide targeted 
treatment. The PARAGON-HF study confirmed 
again that, until now, no single therapy could treat 
HFpEF once and for all. Targeted treatment for 
etiologies and/or comorbidities may be the best 
choice. Proposed herein, it is high time to test 
the therapy principle by randomized clinical trials 
in HFpEF patients with identical or major etiolo-
gies according to the present coding proposal. It 
should be noted that an HFpEF patient could 
belong to one or more subtypes, and they can be 
defined as HFpEF-1, HFpEF-2, or a combination 
of HFpEF-13, HFpEF-135 for example. 
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Table 1. New phenotypic coding for heart failure with preserved ejection fraction (HFpEF).
Phenotypic coding Brief description
HFpEF-1. Vascular- 
-related HFpEF
Hypertension, coronary artery disease, and coronary microvascular dysfunction  
related HFpEF.
HFpEF-2. Cardiomyo-
pathy-related HFpEF
These patients may have hypertrophic cardiomyopathy, infiltrative cardiomyopathies 
like cardiac amyloidosis and Fabry cardiomyopathy which induced the HFpEF.
HFpEF-3. Right heart- 
and pulmonary-related 
HFpEF
Patients in this subtype often have pulmonary hypertension with or without right  
ventricular dysfunction.
HFpEF-4. Valvular- and 
rhythm-related HFpEF
It mainly refers to HFpEF resulting from valvular disease and atrial fibrillation.
HFpEF-5. Extracardiac 
disease-related HFpEF
Extracardiac diseases involve: 
(1) metabolic diseases, such as diabetes mellitus, obesity, or metabolic syndrome; 
(2) diseases that often cause high output state, such as anemia, liver disease,  
hyperthyroidism, and arteriovenous fistula; 
(3) other diseases, such as chronic kidney disease, radiotherapy for cancer, etc.
